Fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), can induce endoplasmic reticulum stress to trigger cancer cell apoptosis and inhibit protective autophagy, thereby sensitizing cancer cells to additional stressors or therapies [85]; it may also indirectly modulate pro-survival signaling pathways such as PI3K/AKT/mTOR and MAPK [86]. This evidence concerns the gene MTOR and cancer.